Notice: This company has been marked as potentially delisted and may not be actively trading. Seneca Biopharma (SNCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends SNCA vs. ADAP, TIL, ELUT, ABOS, BDTX, CADL, FENC, CGEN, CRDL, and CDTXShould you be buying Seneca Biopharma stock or one of its competitors? The main competitors of Seneca Biopharma include Adaptimmune Therapeutics (ADAP), Instil Bio (TIL), Elutia (ELUT), Acumen Pharmaceuticals (ABOS), Black Diamond Therapeutics (BDTX), Candel Therapeutics (CADL), Fennec Pharmaceuticals (FENC), Compugen (CGEN), Cardiol Therapeutics (CRDL), and Cidara Therapeutics (CDTX). These companies are all part of the "medical" sector. Seneca Biopharma vs. Adaptimmune Therapeutics Instil Bio Elutia Acumen Pharmaceuticals Black Diamond Therapeutics Candel Therapeutics Fennec Pharmaceuticals Compugen Cardiol Therapeutics Cidara Therapeutics Seneca Biopharma (NASDAQ:SNCA) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations. Does the media refer more to SNCA or ADAP? In the previous week, Adaptimmune Therapeutics had 9 more articles in the media than Seneca Biopharma. MarketBeat recorded 9 mentions for Adaptimmune Therapeutics and 0 mentions for Seneca Biopharma. Adaptimmune Therapeutics' average media sentiment score of 0.53 beat Seneca Biopharma's score of 0.00 indicating that Adaptimmune Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Seneca Biopharma Neutral Adaptimmune Therapeutics Positive Is SNCA or ADAP more profitable? Adaptimmune Therapeutics has a net margin of -25.43% compared to Seneca Biopharma's net margin of -230.34%. Adaptimmune Therapeutics' return on equity of -74.15% beat Seneca Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Seneca Biopharma-230.34% -122.20% -110.61% Adaptimmune Therapeutics -25.43%-74.15%-15.09% Do analysts prefer SNCA or ADAP? Adaptimmune Therapeutics has a consensus price target of $3.16, indicating a potential upside of 378.01%. Given Adaptimmune Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Seneca Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seneca Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in SNCA or ADAP? 5.2% of Seneca Biopharma shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 2.1% of Seneca Biopharma shares are held by insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, SNCA or ADAP? Seneca Biopharma has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Which has better earnings and valuation, SNCA or ADAP? Seneca Biopharma has higher earnings, but lower revenue than Adaptimmune Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeneca Biopharma$10K4,220.22-$8.35MN/AN/AAdaptimmune Therapeutics$60.28M2.81-$113.87M-$0.22-3.01 Does the MarketBeat Community believe in SNCA or ADAP? Adaptimmune Therapeutics received 302 more outperform votes than Seneca Biopharma when rated by MarketBeat users. However, 63.64% of users gave Seneca Biopharma an outperform vote while only 62.95% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformSeneca BiopharmaOutperform Votes1463.64% Underperform Votes836.36% Adaptimmune TherapeuticsOutperform Votes31662.95% Underperform Votes18637.05% SummaryAdaptimmune Therapeutics beats Seneca Biopharma on 13 of the 16 factors compared between the two stocks. Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get Seneca Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SNCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNCA vs. The Competition Export to ExcelMetricSeneca BiopharmaBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.20M$3.03B$5.21B$8.85BDividend YieldN/A1.86%5.53%4.08%P/E RatioN/A25.7783.3415.60Price / Sales4,220.22312.191,247.8087.92Price / CashN/A172.5640.9736.92Price / Book1.834.607.206.55Net Income-$8.35M-$41.63M$119.63M$226.22M Seneca Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNCASeneca BiopharmaN/A$2.44flatN/A+313.6%$42.20M$10,000.000.007ADAPAdaptimmune Therapeutics2.1303 of 5 stars$0.63-4.5%$3.16+399.5%+47.3%$162.00M$60.28M-2.88449TILInstil Bio2.7456 of 5 stars$24.67+5.6%$145.00+487.8%+252.0%$161.10MN/A-2.1349ELUTElutia2.406 of 5 stars$4.36-0.5%$10.00+129.4%+142.4%$148.50M$24.75M0.00180Gap UpABOSAcumen Pharmaceuticals2.6782 of 5 stars$2.31-2.5%$9.00+290.5%+0.4%$138.48MN/A-1.6751BDTXBlack Diamond Therapeutics2.8355 of 5 stars$2.43flat$15.50+537.9%+8.5%$137.49MN/A-1.7790Positive NewsCADLCandel Therapeutics2.397 of 5 stars$4.14+3.8%$11.00+166.0%+460.0%$134.31M$120,000.00-2.3960Analyst RevisionNews CoverageFENCFennec Pharmaceuticals2.1331 of 5 stars$4.78+3.0%$13.67+185.9%-39.8%$131.12M$21.25M-51.59N/ACGENCompugen3.2131 of 5 stars$1.45+1.4%$4.00+175.9%+117.4%$129.40M$33.46M72.5068Positive NewsCRDLCardiol Therapeutics2.7672 of 5 stars$1.58+0.6%$8.75+455.6%+99.2%$128.52M$60,000.00-4.0020Analyst ForecastAnalyst RevisionNews CoverageGap UpCDTXCidara Therapeutics4.2087 of 5 stars$18.19+20.3%$30.50+67.7%+42.7%$128.24M$63.90M-0.7190News CoverageHigh Trading Volume Related Companies and Tools Related Companies Adaptimmune Therapeutics Alternatives Instil Bio Alternatives Elutia Alternatives Acumen Pharmaceuticals Alternatives Black Diamond Therapeutics Alternatives Candel Therapeutics Alternatives Fennec Pharmaceuticals Alternatives Compugen Alternatives Cardiol Therapeutics Alternatives Cidara Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNCA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seneca Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seneca Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
